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journal soon. Abstracts of the manuscripts are enclosed. 
4. Further investigation with additional research funding is needed to warrant the finding of this 
study. 
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Sincerely Yours, 
Prof DaforDTKhalid Yusoff 
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5.2 Enhanced Executive Summary 
Left ventricular hypertrophy (LVH) is an independent risk factor for the development of heart 
failure, coronary heart disease and stroke. It develops as a result of hemodynamic overload, for 
instance, hypertension. Blood pressure is an important determinant of LVH, and a significant 
proportion of patients with essential hypertension develops this complication. However, this 
condition varies in a wide range of phenotypes, and studies had shown that patients with LVH 
may have near-normal blood pressure, suggesting that development of LVH may be due to an 
independent genetic factor from hypertension. 
LVH can be reversed with anti-hypertensive (anti-HT) agents. Angiotensinogen receptor blocker 
like losartan has been shown to improve the reversal effect. However, it is unknown whether 
using this anti-HT agent alone would be useful in preventing LVH. Hence, identifying HT patients 
with the risk of LVH may allow this hypothesis to be tested, and if successful, would lead to the 
prevention, treatment and improvement of prognosis of LVH. 
We recently carried out a genome-wide scan of copy number variation (CNV) on a group of 
hyptertensive LVH patients and observed a gain of copy number in AGTRII gene in a group of 
patients. We attempted to further investigate the role of CNV of this gene in the pathogenesis of 
LVH. However, we observed no significant contribution of this CNV in the disease complication. 
Therefore in this study, we attempted to investigate the contributions of rare CNV in the 
susceptibility of hypertensive LVH, and subsequently to predict the putative molecular pathways 
in the pathogenesis of LVH. 
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5.3 Introduction 
Left ventricular hypertrophy (LVH) is an independent risk factor for the development of heart 
failure, coronary heart disease and stroke. It develops as a result of hemodynamic overload, for 
instance, hypertension [Gary et al, 2007}. Blood pressure is an important determinant of LVH, 
and significant proportion of patients with essential hypertension develops their complication. 
However, this disease varies in a wide range of phenotype, and studies had shown that patients 
with LVH may have near-normal blood pressure, suggesting that development of LVH may be an 
independent genetic factor from hypertension. 
LVH can be reversed with anti-hypertensive (anti-HT) agents. Angiotensinogen receptor blocker 
like Losartan has been shown to improve the reversal effect. However, it is unknown whether 
using this anti-HT agent alone would be useful in preventing LVH. Hence, identifying HT patients 
with the risk of LVH may allow this hypothesis to be tested, and if successful, would lead to the 
prevention, treatment and improvement of prognosis of LVH. 
Scientific Rationale: 
The normal distribution of LV mass (as an indicator of LVH] in the population indicates the 
involvement of complex and multiple genetic factors to the trait. Various genetic studies had 
been carried out extensively, reporting mainly on the candidate genes like angiotensin 
converting enzyme [ACE], guanine nucleotide-binding protein gene (GNB3), insulin-like growth 
factor (IGF-1), angiotensin II (AGT II), angiotensin receptors (AGTRs) [Doolan et al, 2004; 
Semplicini et al, 2001; Nagy et al., 1999; Lindpaintner et al, 2004; Olszanecka et al., 2003; 
Jeunemaitre et al., 2008) etc but no conclusive result was obtained. Though, this may be more 
indicative of the nature of this complex disease. 
The impact of CNV in common and complex diseases has been well acknowledged since the last 
few years. However, its contribution to the cardiovascular disease such as hypertensive LVH has 
not been reported before. This proposed study hence, attempts to peform a genome-wide scan of 
CNV in patients with hypertensive LVH, and investigate the role of rare CNV in the susceptibility 
this complication. 
Hypothesis: 
We hypothesize that the rare CNVs contribute to the susceptibility of hypertensive LVH. 
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